Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine for Immunological Non-Responders in HIV
NCT07637877Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Drugs
- rilpivirine
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 2, randomised trial of rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: CD4+ T cell count at 36 weeks. Started Jun 2026; status: recruiting.
02
Design
2 arms- Study design
- Randomized
cART
Participants receive standard combination antiretroviral therapy (cART) alone.
cART plus Rilpivirine
Participants receive standard combination antiretroviral therapy (cART) plus rilpivirine.
03
Who it enrols
HIV patients aged 18-65 with incomplete immune reconstitution (CD4+ 200-350 cells/μL) despite suppressive dolutegravir-based ART for >4 years, excluding those with co-infections, recent efavirenz/rilpivirine use, or NNRTI resistance.
04
Endpoints
Primary
CD4+ T cell count
Secondary
Treatment-emergent adverse events
Beyond the preview
Go deeper on NCT07637877.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637877.